Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

polyethylene glycol & electrolytes (Rx, OTC)Brand and Other Names:GoLytely, MiraLax, more...Glycolax, GoEvac, CoLav, CoLyte, NuLYTELY, polyethylene glycol electrolyte soln, polyethylene glycol powder, TriLyte

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

Polyethylene glycol (PEG) content

powder for oral solution

  • 17g/packet
  • 119g
  • 238g
  • 255g
  • 510g
  • 527g
  • 850g
more...

Bowel Preparation

17 g (~1 heaping tbsp) in 8 oz of clear liquid PO q10min until 2 L has been consumed or rectal effluent is clear

NG: 20-30 mL/min

Constipation

17 g in 4-8 oz water PO once daily for ≤1 week

Administration

Refrigerate before administering to improve palatability

Have patient fast 3-4 hr before administering PEG

Encourage rapid drinking of each portion

MiraLax: Bottle top is measuring cup marked to contain 17 g

Advise patients to hydrate adequately before, during, and after use

Dosage Forms & Strengths

PEG content

powder for oral solution

  • 17g/packet
  • 119g
  • 238g
  • 255g
  • 510g
  • 527g
  • 850g
more...

Bowel Preparation

25-40 mL/kg/hr PO for 4-10 hr until rectal effluent is clear; total dose not to exceed 2 L

Constipation

<6 months: Safety and efficacy not established

≥6 months: 0.5-1.5 g/kg PO once daily for no longer than 2 weeks; adjusted to effect; not to exceed 17 g/day

Next

Adverse Effects

Frequency Not Defined

Abdominal bloating

Abdominal cramping

Abdominal distention

Colonic mucosal aphthous ulcerations

Diarrhea

Flatulence

Ischemic colitis

Nausea

Previous
Next

Warnings

Contraindications

Hypersensitivity

Cautions

Osmotic laxative products may produce colonic mucosal aphthous ulcerations, including reports of more serious cases of ischemic colitis necessitating hospitalization

Avoid use in patients with bowel obstruction, megacolon, perforated bowel, ulcerative colitis, toxic colitis, gastric retention

Not indicated for children <2 years because of risk of hypoglycemia, dehydration, and hypokalemia

When using PEG as laxative, do not give for >1 week

Electrolyte imbalance reported with prolonged use

Risk of fluid and electrolyte abnormalities, arrhythmias, seizures, and renal impairment

Use with caution in renal insufficiency; ensure adequate hydration, and consider laboratory testing

Directly observe administration to patients at risk for aspiration

Products are not for direct ingestion but require dilution with water

Previous
Next

Pregnancy & Lactation

Pregnancy category: C

Lactation: No data available

Pregnancy Categories

A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA:Information not available.

more...
Previous
Next

Pharmacology

Mechanism of Action

Osmotic laxative; causes water retention in stool, causing increase in stool frequency

Absorption

Not absorbed

Bioavailability: 0.2%

Onset: 24-96 hr

Elimination

Excretion: Feces (93%), urine (0.2%)

Previous
Next

Images

Previous
Next

Formulary

FormularyPatient Discounts

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Add or Remove Plans
Plans for
Select State:
Non-Medicare PlansMedicare Plans

Select a box to add or remove a plan.

Select a class to view formulary status for similar drugs

Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.